Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience-Reference-Cited by-同舟云学术

Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience

Published:2017-11-16 Issue:5 Volume:20 Page:898-906
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Fornaro Alessandra¹²,Olivotto Iacopo¹,Rigacci Luigi³,Ciaccheri Mauro¹,Tomberli Benedetta¹,Ferrantini Cecilia¹⁴,Coppini Raffaele⁵,Girolami Francesca¹,Mazzarotto Francesco¹⁴⁶,Chiostri Marco⁷,Milli Massimo²,Marchionni Niccolò⁴⁸,Castelli Gabriele¹

Affiliation:

1. Cardiomyopathy Unit; Careggi University Hospital; Florence Italy

2. Cardiology Unit; S. Maria Nuova Hospital; Florence Italy

3. Hematology Unit; Careggi University Hospital; Florence Italy

4. Department of Clinical and Experimental Medicine; University of Florence; Italy

5. Department NEUROFARBA; University of Florence; Italy

6. Cardiovascular Research Centre; Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; London UK

7. Intensive Cardiac Care Unit, Heart and Vessel Department; Careggi University Hospital; Florence Italy

8. Cardiothoracovascular Department; Careggi University Hospital; Florence Italy

Funder

Italian Ministry of Health

Telethon Italy

ToRSADE

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Cancer treatment and survivorship statistics, 2014;DeSantis;CA Cancer J Clin,2014

2. Projections of the cost of cancer care in the United States: 2010-2020;Mariotto;J Natl Cancer Inst,2011

3. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects;Carver;J Clin Oncol,2007

4. Cancer therapy-related cardiac dysfunction and heart failure. Part 2: prevention, treatment, guidelines, and future directions;Hamo;Circ Heart Fail,2016

5. Heart failure therapies for end-stage chemotherapy-induced cardiomyopathy;Mukku;J Card Fail,2016

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity;Biochemical and Biophysical Research Communications;2024-01

2. Assessment of anthracycline-induced cardiotoxicity in childhood cancer survivors during long-term follow-up using strain analysis and intraventricular pressure gradient measurements;Heart and Vessels;2023-11-16

3. The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy;JACC: CardioOncology;2023-10

4. Myeloperoxidase is a critical mediator of anthracycline-induced cardiomyopathy;Basic Research in Cardiology;2023-09-01

5. Research progress of extracellular vesicles and exosomes derived from mesenchymal stem cells in the treatment of oxidative stress-related diseases;Frontiers in Immunology;2023-08-14